Objective-Aortic valve disease, including calcification, affects >2% of the human population and is caused by complex interactions between multiple risk factors, including genetic mutations, the environment, and biomechanics. At present, there are no effective treatments other than surgery, and this is because of the limited understanding of the mechanisms that underlie the condition. Previous work has shown that valve interstitial cells within the aortic valve cusps differentiate toward an osteoblast-like cell and deposit bone-like matrix that leads to leaflet stiffening and calcific aortic valve stenosis. However, the mechanisms that promote pathological phenotypes in valve interstitial cells are unknown. Approach and Results-Using a combination of in vitro and in vivo tools with mouse, porcine, and human tissue, we show that in valve interstitial cells, reduced Sox9 expression and nuclear localization precedes the onset of calcification. In vitro, Sox9 nuclear export and calcific nodule formation is prevented by valve endothelial cells. However, in vivo, loss of Tgfβ1 in the endothelium leads to reduced Sox9 expression and calcific aortic valve disease. Conclusions-Together, these findings suggest that reduced nuclear localization of Sox9 in valve interstitial cells is an early indicator of calcification, and therefore, pharmacological targeting to prevent nuclear export could serve as a novel therapeutic tool in the prevention of calcification and stenosis. (Arterioscler Thromb Vasc Biol. 2016;36:328-338. The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
C alcific aortic valve disease (CAVD) is the most prevalent valvular disorder accounting for ≈55 000 hospitalizations and 15 000 deaths annually in the United States. 1 To date, no preventative medical therapies exist, and valve replacement surgery remains the only effective treatment for this disease. 2 Despite the high morbidity and mortality rates, the molecular mechanisms underlying CAVD remain largely unknown. 1 The normal aortic valve (AoV) is composed of 3 cusps, and function is largely achieved by a highly organized connective tissue consisting of 3 layers of diversified extracellular matrix (ECM) and 2 major cell populations. The ECM provides all the necessary biomechanical properties for coaptation during the cardiac cycle and predominantly consists of collagens, proteoglycans, and elastin arranged relative to blood flow. The stratified ECM is established and maintained by valve interstitial cells (VICs) that reside within the core of mature cusps as quiescent fibroblast-like cells in the absence of disease. The valve cusps are encapsulated by a single layer of valve endothelial cells (VECs) that serve as a physical barrier between VICs and the hemodynamic environment. In addition, findings from in vitro studies suggest that VECs may influence VIC behavior and ECM production. [3] [4] [5] Together, the extracellular and cellular components of the valve create an integrated and balanced connective tissue to maintain heart valve structure and function throughout life.
CAVD is a progressive disorder characterized by alterations in connective tissue homeostasis that result in valve stiffening and incomplete opening. 6 Although the precise pathogenesis of CAVD remains unknown, mutations in NOTCH1 have been associated with AoV disease in humans, 7 and a variety of nongenetic risk factors, including diabetes mellitus, aging, hypertension, hypercholesterolemia, and smoking, have been identified. 8 CAVD pathogenesis is complex, and although once thought of as a degenerative disorder, it is now considered an active process whereby quiescent VICs undergo phenotypic changes and ectopically express osteogenic markers, including Runx2, Osteocalcin, and Spp1, that facilitate deposition of mineralized ECM and formation of calcific nodules. 3, 8, 9 These cellular and extracellular changes alter valve biomechanics and lead to a less flexible and more stiffened cusp that progressively results in stenosis and impaired blood flow. Although the contribution of VICs in the formation of calcific nodules has been well studied in CAVD, little is known about how this process is initiated.
We previously showed that the transcription factor Sox9 is highly expressed in VICs and plays a causative role in the onset of AoV disease. 10, 11 Sox9 fl/+ ;Col2a1-cre mice develop early onset calcification phenotypes with an associated downregulation of healthy cartilaginous ECM proteins. 10, 11 These phenotypes are consistent with the diverse roles of Sox9 in positively regulating chondrogenic target genes (type II collagen, aggrecan, cartilage link protein) and repressing osteogenic markers (RUNX2, Spp1) in the developing skeletal system. 9, [12] [13] [14] [15] [16] [17] [18] Although our previous studies identified a causative role for reduced Sox9 function in CAVD in mice, the mechanisms of its regulation have yet to be determined. The valve endothelium has been shown to regulate VIC phenotypes in vitro, 5, [19] [20] [21] and in human patients, endothelial cell dysfunction accelerates the onset and progression of many cardiovascular diseases. [22] [23] [24] [25] In this current study, we examine the role of the valve endothelium in the regulation of Sox9 in CAVD and for the first time identify a hierarchical signaling pathway emanating from the VECs that is essential for maintaining Sox9 nuclear localization in VICs to prevent calcific nodule formation.
Materials and Methods
Detailed Materials and Methods can be found in the online-only Data Supplement.
Cell Culture Systems
Porcine AoV interstitial cells (pAVIC), porcine AoV endothelial cells (pAVEC), and murine VECs and Tgfβ1 fl/fl AoV explants were isolated as described. 26, 27 pAVICs were either cultured alone, cocultured with endothelial cells, or treated with transforming growth factor β1 (Tgfβ1), Leptomycin B, adenovirus against Cre (AdV-Cre), green fluorescent protein (AdV-GFP), or Y27632 as described in the online-only Data Supplement.
Generation of Mice
Homozygotes Tgfβ1 fl/fl ;Nfatc1ENCre + and Cre negative (Tgfβ1 fl/fl ; Nfatc1ENCre − ) littermate controls were generated by breeding Tgfβ1 fl/fl females (Jackson Laboratories) with Nfatc1ENCre +28 males. Hypercholesterolemic Reversa mice and normocholesterolemic controls were obtained from Dr Donald Heistad. 29 Histological and molecular analyses were performed on AoVs from experimental and control mice at the indicated time points.
Human AoV Specimens
Human diseased AoV specimens (n=3) were obtained from patients undergoing valve replacement surgery, whereas control AoVs (n=3) were collected from age-matched individuals at the time of autopsy who died of noncardiac causes. Additional information can be found in the online-only Data Supplement.
Results

Sox9 Nuclear Localization Is Reduced in VICs and Precedes Calcification In Vitro
Reduced Sox9 function in vivo promotes calcific AoV phenotypes, suggesting a causative role. 10, 11 To examine the regulatory mechanisms of Sox9 in the onset of calcification, we used an in vitro pAVIC calcification system. After 7 days of culture on glass, pAVICs formed calcific nodules as detected by Alizarin Red staining ( Figure 1A-1C ). This was associated with reduced Sox9 expression and nuclear localization ( Figure 1D -1E) and led to decreased Col2a1 (chondrogenic) and increased Runx2 (osteogenic; Figure 1F ). To determine whether these changes were associated with apoptosis, Cleaved Caspase-3 expression was examined by Western blot, but insignificant differences were observed between days 1 and 7 ( Figure IIA in the online-only Data Supplement). However, it should be noted that Western blot analysis identifies Cleaved Caspase-3 expression in the entire cell population, and therefore, associations between Alizarin Red reactivity and apoptosis cannot be made at the single cell level, but should be considered for future work. The progressive loss of Sox9 nuclear localization in cultured pAVICs began as early as 24 hours after culture ( Figure 1G ), suggesting that this precedes calcific nodule formation detected at day 7. To determine whether the nuclear export signal of Sox9 is required for this process, pAVICs were treated with 5ng/mL of the nuclear export signal inhibitor Leptomycin B for 7 days. As shown, treatment retained Sox9 in the nucleus ( Figure 1I versus 1H) and significantly attenuated Alizarin Red reactivity ( Figure IJ ) and Runx2 expression ( Figure 1K ). These studies suggest that Sox9 nuclear localization is reduced in VICs before the onset of calcification in vitro, and this process is dependent on the nuclear export signal.
Reduced Sox9 Expression in VICs Is Associated With Calcification in Humans and Mice
Although our work has alluded to a role for Sox9 in valve calcification in mice, 10 during the neonatal period because of respiratory distress, and echocardiograms are not routinely performed. 30, 31 Therefore, causative links of SOX9 misexpression to human AoV disease has been challenging. Here, we examined correlations between Sox9 expression in valve tissue excised from humans (≈70 years) undergoing surgical AoV replacement as a result of end-stage calcification and stenosis. As shown in Figure  2B , SOX9 was significantly reduced in VICs located close to the calcific region ( Figure 2B , *) compared with age-matched nondiseased controls (Figure 2A , arrows). Interestingly, of the remaining SOX9 expression in diseased valves, its localization was predominantly cytoplasmic ( Figure 2B , arrowhead, inset box). By Western blot, nuclear SOX9 expression was undetectable in calcified adult valves, whereas adult controls and pediatric noncalcified diseased valves expressed an abundance ( Figure 2C and 2D). Cytoplasmic SOX9 was also reduced in CAVD patients; however, this effect was not as dramatic as changes in nuclear expression. These findings suggest that reduced Sox9 expression correlates with CAVD in the human population; however, because these samples were taken from end-stage disease, we are unable to distinguish between cause and effect. Reversa mice serve as an established mouse model of hypercholesterolemia-induced CAVD ( Figure 2G and 2H), and by immunohistochemistry, Sox9 expression was reduced in AoVs compared with normocholesterolemic controls ( Figure 2E and 2F). Interestingly, reduced Sox9 expression was noted in 11-, but not in 3-, month-old Reversa mice (Figures IIIC and IIID in the online-only Data Supplement) before the onset of calcification detected at 22 months ( Figure 2G and 2H). Together, these findings suggest that reduced Sox9 expression is associated with AoV calcification in human patients and occurs before the deposition of calcified nodules in a hypercholesterolemic mouse model.
Endothelial Cells Maintain Sox9 Nuclear Localization in VICs and Attenuate Calcification
To examine the role of VECs in regulating Sox9 expression and calcification, pAVICs were cocultured in a transwell assay in the absence ( Figure 3A and 3C) or presence ( Figure 3B and 3D) of pAVECs. After 7 days, Alizarin Red detected calcification in pAVICs-cultured alone ( Figure 3A , arrows); however, in the presence of pAVECs, this was attenuated ( Figure 2B ). Similar to Figure 1D , calcification was associated with reduced Sox9 nuclear localization ( Figure 3C ); however, nuclear expression was retained by pAVECs ( Figure 3D ). This finding was supported by Western blot showing increased Sox9 nuclear expression in pAVIC/pAVEC cocultures ( Figure 3E and 3F), which was associated with increased expression of the transcriptional target gene Col2a1 ( Figure 3G ). The ability of VECs to protect VICs against calcification by retaining Sox9 nuclear localization was also observed in human VIC cocultures with human umbilical vein endothelial cell ( Figure  IV in the online-only Data Supplement), suggesting conservation across species. As the transwell system is designed to prevent physical contact between endothelial cells and VICs, we hypothesized that the factor emanating from VECs to prevent calcification in VICs is secreted.
Tgfβ1 Treatment Is Sufficient to Promote Sox9 Nuclear Localization and Prevent Calcification of pAVICs
In heart valves, Sox9 expression and localization has been shown to be regulated by several signaling pathways, including BMP2, Notch1, and β-catenin. [32] [33] [34] However based on their mechanisms of action and patterns of expression, we excluded these as candidates for the VEC-mediated regulation of Sox9 in VICs. Tgfβ1 and its downstream signaling mediator pSmad2 are highly enriched in VECs compared with VICs 35 (Figure VA -VC in the online-only Data Supplement).
To determine whether Tgfβ1 is sufficient to recapitulate the protective effects of VECs on VIC-mediated calcification, pAVICs were plated for 48 hours and treated with human recombinant TGFβ1 (10 ng/mL) or BSA every 48 hours for an additional 5 days. As shown in Figure 4A , TGFβ1 treatment attenuated calcification compared with BSA as indicated by Alizarin Red reactivity. In addition, TGFβ1 treatment reestablished Sox9 nuclear localization in pAVICs ( Figure 4B ) similar to coculture with pAVECs, and this was associated with increased Col2a1 and decreased Runx2 ( Figure 4C ). To further investigate this, whole postnatal AoV explants from Tgfβ1 fl/fl mice were cultured and treated with a AdV-Cre or AdV-GFP ( Figure 4D and 4E) . von Kossa staining revealed that AdV-Cre treatment increased calcium deposition ( Figure 4D-4F ) as a result of Tgfβ1 knockdown ( Figure 4G ) and decreased Sox9 expression ( Figure 4H and 4I) . To further support a role for Tgfβ1 signaling in this process, pAVICs were cocultured in a transwell assay with Tgfβ1 fl/fl CD31+ murine cardiac endothelial cells and treated with AdV-Cre or AdV-GFP. After 48 hours, cocultured pAVICs treated with AdV-Cre similarly developed calcific nodules ( Figure VD -VF in the online-only Data Supplement). To determine whether TGFβ1 treatment affected Sox9 function, luciferase assays were performed in pAVICs using plasmids containing the minimal promoter and Sox9-responsive intron 1 of Col2a1 (4x48bp-Col2a1) or just the minimal promoter lacking SRY (sex determining region Y)-binding sites (-89-+6bp-Col2a1). As shown, TGFβ1 treatment increases the transcriptional activity of 4x48bp-Col2a1, and this was dependent on Sox9 response elements ( Figure 4J ). To confirm that Tgfβ1 signaling emanating from VECs was responsible for maintaining Sox9 nuclear localization and preventing VIC-mediated calcification, transwell assays were repeated in the presence of the TGFβ1-receptor inhibitor, SB431542. As shown in Figure 4K 
Rho Kinase Is Required for Tgfβ1-Mediated Sox9 Regulation in pAVICs
In chondrocytes, Rho kinase (ROCK) functions downstream of Tgfβ1, 36 and therefore, to determine whether ROCK facilitates Tgfβ1-mediated Sox9 nuclear localization, pAVICs were pretreated with the inhibitor Y27632 before TGFβ1 exposure. pSmad is increased with Tgfβ1 treatment, but the addition of the ROCK inhibitor does not significantly affect levels, suggesting that Smad and ROCK function through differential Tgfβ1-mediated signaling pathways ( Figure 5C ). Col2a1 expression is increased in response to TGFβ1, and this affect seems to be dependent on ROCK activity ( Figure 5D ). From these data, we speculated that ROCK might regulate Sox9 via phosphorylation, and published reports have shown that phosphorylation at Serine (S) 64 and 181 drive nuclear localization. 36 To test this, we performed luciferase assays and show that compared with wild-type Sox9, transactivation of Col2a1 was attenuated (≈20%) when cotransfected with an S64 and S181 mutant ( Figure 5E ). Interestingly, inhibition of ROCK activity alone by Y27632 was sufficient to increase Alizarin Red reactivity in cultured pAVICs after 48 hours ( Figure 5F and 5G). These observations suggest that Sox9 phosphorylation by ROCK may play a role in VIC-mediated calcification.
Targeted Deletion of Tgfβ1 in VECs Leads to Aortic Valve Disease In Vivo
To investigate whether endothelial Tgfβ1 plays a role in AoV disease in vivo, we targeted loss of function using an Nfatc1ENCre transgenic line that recombines in VECs, but not VICs or any other endothelial cells other than the early endocardium 28 ;Nfatc1ENCre + mice were thickened, and Sox9 was detected at high levels in VICs in the absence of calcification (Figure 6A , 6B, and 6G). At 3 months ( Figure 6D ), Sox9 expression was dramatically reduced by immunohistochemistry ( Figure 6D . As Sox9 is a potent positive regulator of collagen, trichrome staining was performed at 6 months ( Figure  VII and VIIJ in the online-only Data Supplement); however, no significant differences were noted relative to increased thickness, although Col2a1 was reduced at 3 months ( Figure VIIC and VIID in the online-only Data Supplement). The phenotypic changes in cusp thickness and calcification at 6 months of age were associated with subtle, but significant increased AoV peak velocity ( Figure 6H ) and blood flow regurgitation ( Figure VIK and VIL in the online-only Data Supplement) as determined by echocardiography. Together, these data imply that loss of Tgfβ1 in VECs leads to reduced Sox9 expression in VICs at 3 months, which precedes calcification onset and associated dysfunction detected at 6 months in vivo.
Discussion
Calcific aortic stenosis is the most predominant form of valve pathology affecting >25% of adults over the age of 65. 1 At present, there are no effective treatments other than interventional surgery, and pharmacological mechanistic-based therapies can only be developed if the regulatory processes that initiate CAVD onset and progression are identified. In this current study, we expand on our previous work demonstrating a causative role for the transcription factor Sox9 in CAVD 10, 11 and show that Tgfβ1 signaling from VECs is essential for promoting Sox9 nuclear localization in VICs to prevent calcification. In two CAVD mouse models (Tgfβ1 fl/fl ;Nfatc1ENCre + , hypercholesterolemia), and a calcification in vitro assay, reduced Sox9 expression in VICs preceded calcific nodule formation, supporting a role during early stages of disease onset. This study directly shows that VEC dysfunction at the level of regulatory pathways is sufficient to promote CAVD and, in addition, highlight the potential of targeting Sox9 nuclear localization as a novel therapeutic strategy.
There is strong evidence to show that the process of calcification is mediated by VICs as a result of abnormal activation, apoptosis, ECM remodeling, and calcium deposition. 37 However, based on findings from other cardiovascular diseases, it has been speculated that dysfunction of the valve endothelium could also play a role. Here, we show that VECs prevent calcific nodule formation by VICs (Figure 3 ; Figure  IV in the online-only Data Supplement), consistent with other reports demonstrating a protective role for the valve endothelium against disease processes. 5, 19, 21, 38 In vivo, VECs are in direct contact with the hemodynamic environment and, therefore, exposed to shear stress and circulating signaling molecules, cytokines, and risk factors, including cholesterol, lipids, and inflammatory cells. As the VECs encapsulate the valve cusp, VICs do not experience the same exposure, yet mediate pathological processes in response to abnormal mechanical stress or risk factor exposure. 19, 20, 39 Therefore, VECs likely serve as sensors and molecularly relay external information to underlying VICs within the leaflets during both pathological and physiological conditions, and if damaged, lost, or injured, these protective mechanisms are likely lost, and the VICs lose their molecular communications and become directly exposed to the external environment.
In this current study, we identify Tgfβ1 signaling as a critical VEC-mediated growth factor that positively regulates Sox9 expression and nuclear localization in VICs (Figure 4 ) via ROCK ( Figure 5 ) to prevent calcification. Our findings also suggest that in addition to being anticalcific, this pathway also promotes chondrogenic-like phenotypes (Figures 1F, 3G , and 4C) in pAVICs, consistent with our previous work 10 and suggesting pivotal roles in heart valve homeostasis. Tgfβ1 is predominantly localized to VECs ( Figure VIA in the onlineonly Data Supplement), 35 whereas Tgfβ2 and Tgfβ3 seem more widespread throughout the VIC population. These ligands, along with their receptors, play multiple roles in valve development, 40, 41 and inhibition of Tgfβ signaling in mouse models of myxomatous degeneration alleviates valvular phenotypes, suggesting Tgfβ-dependency in disease states. [42] [43] [44] [45] [46] [47] [48] [49] We recognize that findings from our study are dissimilar to previous reports, showing that Tgfβ1 treatment and ROCK inhibition are pro-osteogenic in cultured VICs. 47, [49] [50] [51] The reasons for such disparities in response to increased Tgfβ1 signaling or Y27632 treatment in vitro are unclear, but could be dependent on the sensitivity of culture conditions, including VIC passage number, 52 species, 53 cell contacts, 54 substrate, 51 endothelial cell contamination, 19 Tgfβ1 dosage, and endogenous Sox9 levels. In vivo, the pro-osteogenic dependency of Tgfβ1 in heart valves has not been reported, and this study is the first to suggest that regulated levels of Tgfβ1 secretion by VECs are required to maintain valve homeostasis and prevent calcification, whereas loss of function in VECs could be pathogenic. In vivo, the environment is different from in vitro conditions, and as Tgfβ and ROCK signaling are responsive to biomechanical cues, the hemodynamic environment or valve compliance could also influence their mechanisms of action on downstream targets and the pathological process.
Although this study has shown that increased Tgfβ1 signaling in VECs prevents calcification mediated by VICs, systemic therapeutic targeting of Tgfβ1 could be problematic based on its wide-spread function in many systems and possible dosage dependency in the valves as discussedearlier. Therefore, nuclear retention of Sox9 in VICs would be an attractive alternative in the prevention of calcification. CRM1dependent nuclear export signal is required for nuclear export of Sox9 during the process of calcification as Leptomycin B treatment attenuated calcification in vitro ( Figure 1H-1K ). In addition, our findings suggest that promoting phosphorylation or preventing phosphatase activity at S64 and S181 may be an additional mechanism to maintain Sox9 in the nuclei of VICs and prevent disease onset and progression ( Figure 5E ). However, therapeutic targeting of Sox9 localization needs to be tightly regulated because we show that this transcription factor plays pivotal roles in osteogenic and chondrogenic programs. Although reduced nuclear localization increases Runx2 (osteogenic), this is at the expense of Col2a1 (chondrogenic; Figure 1F ). Similarly, nuclear retention of Sox9 in pAVICs by the presence of endothelial cells ( Figure 3G ) or Tgfβ1 ( Figure 4C ) attenuates calcification (Runx2), but significantly increases Col2a1. Therefore, homeostatic mechanisms need to be considered.
Interestingly, although our data shows that calcification is associated with reduced Sox9 nuclear localization, we do not observe significant increases in cytoplasmic localization. This could be because of rapid degradation of cytoplasmic or unphosphorylated Sox9, and this may explain why an overall reduction in Sox9 expression and not nuclear localization is observed in Tgfβ1 fl/fl ;Nfatc1ENCre + mice; however, further work is required to test this. The relevance of nuclear Sox9 to prevent calcific nodule formation by VICs is intriguing, and we and others have shown that as a transcription factor, Sox9 binds and positively regulates cartilaginous matrix genes highly expressed in the valves and represses osteogenic gene programs associated with valve calcification, including Spp1 and Runx2. 9, [12] [13] [14] [15] [16] [17] [18] Therefore, suggesting that in the nuclei of VICs, Sox9 plays pivotal transcriptional roles in promoting healthy (cartilaginous) phenotypes and preventing calcification, which are dysregulated in valve disease ( Figure VIII in the online-only Data Supplement). Interestingly, we observe Sox9 expression in VECs of 3-month-old wild-type animals ( Figure 6C) , and although this cell type do not typically undergo osteoblast-like changes, it is considered that Sox9 may play an additional role related to maintaining endothelial integrity, which if disrupted may have secondary effects on calcification.
